Insider Purchases: Inside the Buy
Tag: Insider Purchases
🫀 Boston Scientific (BSX): The CEO Just Bought $9 Million. Is Wall Street Missing Something?
Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
❄️ Hudson Technologies (HDSN): The Entire Board Bought. Should Investors Pay Attention?
Hudson Technologies isn't the hottest stock on Wall Street—but it may be one of the coolest. After synchronized insider buying from management, directors and a major shareholder, we examine whether this overlooked refrigerant specialist deserves a closer look.
🥫 The Great Canned-Good Reset: Inside Conagra's Dividend Cut, Brase's $510K Skin-in-the-Game, and the 10x Forward P/E Floor
Conagra's 50% dividend cut shocked income investors—but the story didn't end there. With CEO John Brase buying more than $510,000 of stock, debt moving lower, and shares trading around 10x forward earnings, the turnaround thesis deserves another look.
🏥 Elevance Health (NYSE: ELV): The CEO Bought Again. We're Still Buying the Story.
Exactly one year after publishing our original bullish thesis on Elevance Health, we're revisiting the story. Shares are up nearly 26%, yet the core investment case remains surprisingly intact. CEO Gail Boudreaux just bought another $1 million worth of stock, institutions continue to hold over 93% of shares, and valuation still looks attractive.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🚀 Insperity (NSP): Why the CEO Just Bought Another $7.9M of This HR Stock
Insperity (NYSE: NSP) continues attracting major insider buying. CEO Paul Sarvadi has now purchased roughly $15.5 million of stock in less than three months, including a new $7.9 million purchase after shares rallied nearly 50%.
📈 Top Insider Buys April 2026: PRLD, THM, TORO, SMPL & More
Insiders are buying across biotech, mining, shipping, AI, banking, snacks, water infrastructure, and cybersecurity. Here’s what the biggest Week 3 April 2026 buys may signal.
SSP Stock Analysis 2026: Scripps Insiders Double Down on a High-Stakes Media Turnaround
When insiders start buying stock aggressively, investors take notice. In early 2026, executives, directors, and members of the Scripps family all stepped in to buy SSP shares. The question now: is this a deep-value media turnaround or a value trap?
KKR: The Private Equity Giant Offering Public-Scale Prosperity
KKR is no longer just for billionaires in wood-paneled boardrooms. With insiders buying, earnings compounding, and shares still ~38% below highs, the private equity giant looks like public-scale opportunity.